Kamada Ltd. (NASDAQ:KMDA) Short Interest Down 25.0% in August

Key Points

• Kamada Ltd. experienced a **25.0% decrease** in short interest for August, with total short interest dropping to **50,200 shares** from 66,900 shares earlier in the month.
• The company reported **$0.13 EPS** for the last quarter, surpassing the consensus estimate of **$0.09**, despite revenue being significantly lower than expected at **$44.75 million**.
• Kamada's stock is currently rated as a **"Moderate Buy"** with an average target price of **$13.00**, reflecting positive sentiment from analysts after a recent upgrade to "strong-buy."

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) saw a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 50,200 shares, a decline of 25.0% from the August 15th total of 66,900 shares. Based on an average trading volume of 61,400 shares, the short-interest ratio is currently 0.8 days. Approximately 0.2% of the company's stock are sold short. Approximately 0.2% of the company's stock are sold short. Based on an average trading volume of 61,400 shares, the short-interest ratio is currently 0.8 days.

Kamada Trading Down 0.6%

Kamada stock traded down $0.04 during mid-day trading on Friday, hitting $6.91. The stock had a trading volume of 35,913 shares, compared to its average volume of 46,458. The firm's 50 day moving average is $7.24 and its 200 day moving average is $7.01. Kamada has a one year low of $5.17 and a one year high of $9.15. The firm has a market capitalization of $397.39 million, a P/E ratio of 20.32, a P/E/G ratio of 0.73 and a beta of 0.89.

Kamada (NASDAQ:KMDA - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.09 by $0.04. Kamada had a net margin of 11.22% and a return on equity of 7.41%. The business had revenue of $44.75 million during the quarter, compared to the consensus estimate of $158.59 million. Kamada has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Kamada will post 0.23 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in KMDA. Trexquant Investment LP bought a new position in shares of Kamada during the 1st quarter valued at about $82,000. Cubist Systematic Strategies LLC bought a new position in shares of Kamada during the 1st quarter valued at about $206,000. Jump Financial LLC bought a new position in shares of Kamada during the 2nd quarter valued at about $219,000. NewEdge Advisors LLC boosted its holdings in shares of Kamada by 119.9% during the 1st quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company's stock valued at $341,000 after purchasing an additional 28,165 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Kamada in the 2nd quarter valued at about $472,000. Institutional investors own 20.38% of the company's stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.